Should I buy or sell Biohaven stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares. View BHVN analyst ratings or view top-rated stocks .

What is Biohaven's stock price target for 2024?

5 analysts have issued 12-month price targets for Biohaven's stock. Their BHVN share price targets range from $24.00 to $36.00. On average, they expect the company's stock price to reach $29.17 in the next twelve months. This suggests that the stock has a possible downside of 12.3%. View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts .

How have BHVN shares performed in 2023?

Biohaven's stock was trading at $13.88 at the beginning of 2023. Since then, BHVN stock has increased by 139.6% and is now trading at $33.25. View the best growth stocks for 2023 here .

Are investors shorting Biohaven?

Biohaven saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 6,180,000 shares, a decrease of 8.0% from the October 31st total of 6,720,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 5.3 days. Approximately 10.5% of the company's shares are sold short. View Biohaven's Short Interest .

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our BHVN earnings forecast .

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) announced its earnings results on Tuesday, November, 14th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.33) by $0.17.

What ETFs hold Biohaven's stock?

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) . Invesco Dorsey Wright Healthcare Momentum ETF (PTH) .

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV) , NVIDIA (NVDA) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , ACADIA Pharmaceuticals (ACAD) , QUALCOMM (QCOM) , Pfizer (PFE) , Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT) .

When did Biohaven IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven's major shareholders?

Biohaven's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (8.44%), FMR LLC (4.77%), Armistice Capital LLC (2.98%), Avidity Partners Management LP (1.88%), Adage Capital Partners GP L.L.C. (1.82%) and Northern Trust Corp (0.81%). Insiders that own company stock include Declan Doogan , Elyse Stock , George C Clark , Gregory Bailey , James Engelhart , John W Childs , Julia P Gregory , Matthew Buten and Vlad Coric. View institutional ownership trends .

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Biohaven Stock Price, News & Analysis (NYSE:BHVN)

$33.32

-0.18 (-0.54%)

(As of 04:00 PM ET)

Compare

Today's Range: $32.96
▼
$34.15
50-Day Range: $22.96
▼
$33.96
52-Week Range: $12.35
▼
$34.21

Volume: 672,334 shs
Average Volume: 1.05 million shs
Market Capitalization: $2.67 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.17

Biohaven MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 12.3% Downside
$29.17 Price Target
Short Interest: Healthy
10.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.09
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$3.40 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($5.23) to ($5.01) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

788th out of 949 stocks

Pharmaceutical Preparations Industry

348th out of 408 stocks

1.5

Analyst's Opinion

Consensus Rating
Biohaven has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.17, Biohaven has a forecasted downside of 12.3% from its current price of $33.25.
Amount of Analyst Coverage
Biohaven has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
10.49% of the float of Biohaven has been sold short.
Short Interest Ratio / Days to Cover
Biohaven has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Biohaven has recently decreased by 8.04%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Biohaven does not currently pay a dividend.
Dividend Growth
Biohaven does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BHVN.

2.8

News and Social Media Coverage

News Sentiment
Biohaven has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Biohaven this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,402,138.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
15.50% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
89.60% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biohaven are expected to grow in the coming year, from ($5.23) to ($5.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biohaven is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biohaven is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biohaven has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Biohaven Stock (NYSE:BHVN)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

BHVN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BHVN Stock News Headlines

December 3, 2023 | americanbankingnews.com

Biohaven (NYSE:BHVN) Trading Down 2.6%

December 1, 2023 | finance.yahoo.com

Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting

December 6, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

November 29, 2023 | markets.businessinsider.com

Buy Rating for Biohaven Ltd. on Strong BHV-7000 Prospects in MDD and Epilepsy Markets

November 27, 2023 | msn.com

Biohaven (BHVN) Price Target Increased by 19.39% to 34.34

November 22, 2023 | finance.yahoo.com

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

November 21, 2023 | markets.businessinsider.com

Buy Rating for Biohaven Ltd.: Promising Developments in BHV-1300 and BHV-7000 Programs and Potential Offset of Operating Expenses

November 15, 2023 | finance.yahoo.com

Biohaven Ltd (BHVN) Reports Q3 2023 Financial Results: Advances in Clinical Programs and Strong ...

December 6, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 14, 2023 | nl.investing.com

Biohaven Pharma winst lager dan voorspeld, omzet volgens verwachting

November 14, 2023 | finance.yahoo.com

Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments

November 6, 2023 | finance.yahoo.com

Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why

October 31, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?

October 31, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?

October 19, 2023 | finance.yahoo.com

Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going

October 16, 2023 | finance.yahoo.com

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

October 12, 2023 | finance.yahoo.com

Biohaven Independent Director Acquires 8.0% More Stock

October 9, 2023 | finance.yahoo.com

With 73% ownership of the shares, Biohaven Ltd. (NYSE:BHVN) is heavily dominated by institutional owners

October 6, 2023 | benzinga.com

Biohaven Chief Financial Officer Trades Company's Stock

October 6, 2023 | msn.com

Biohaven raises $258.7M from public offering

October 6, 2023 | finance.yahoo.com

Insider Buying: CFO Matthew Buten Acquires 22,727 Shares of Biohaven Ltd (BHVN)

October 6, 2023 | markets.businessinsider.com

Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler

October 3, 2023 | nasdaq.com

Biohaven Prices Public Offering Of 10.23 Mln Shares At $22/shr

October 3, 2023 | finance.yahoo.com

Here's What Could Help Biohaven Ltd. (BHVN) Maintain Its Recent Price Strength

October 3, 2023 | finance.yahoo.com

Biohaven Announces Pricing of $225 Million Public Offering of Common Shares

October 2, 2023 | msn.com

Biohaven proposes $200M stock offering

September 27, 2023 | finance.yahoo.com

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

See More Headlines

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:BHVN
Previous Symbol: NASDAQ:BHVN
CUSIP: N/A
CIK: 1689813
Web: www.biohavenpharma.com
Phone: 203-404-0410
Fax: N/A
Employees: 928
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $29.17
High Stock Price Target: $36.00
Low Stock Price Target: $24.00
Potential Upside/Downside: -12.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-570,280,000.00
Net Margins: N/A
Pretax Margin: -255.54%
Return on Equity: -110.06%
Return on Assets: -85.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.99
Quick Ratio: 4.99

Sales & Book Value

Annual Sales: $462.51 million
Price / Sales: 5.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.90 per share
Price / Book: 4.24

Miscellaneous

Outstanding Shares: 80,230,000
Free Float: 67,798,000
Market Cap: $2.69 billion
Optionable: Optionable
Beta: 1.03

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Vladimir Coric M.D. (Age 52)
Chairman & CEO
Comp: $1.85M
Mr. Matthew Buten (Age 62)
Chief Financial Officer
Comp: $939.45k
Dr. Bruce D. Car DACVP (Age 61)
Ph.D., Chief Scientific Officer
Comp: $646.89k
Ms. Deb Young
Director of Regulatory Affairs & Operations
Mr. George C. Clark (Age 39)
VP & Chief Accounting Officer
Ms. Jennifer Porcelli
Vice President of Investor Relations
Mr. Warren Volles J.D.
General Counsel & Chief Legal Officer
Mr. Clifford Bechtold M.S.
Chief Compliance Officer
Ms. Kimberly Gentile (Age 57)
Senior Vice President of Clinical Operations
Mr. John Tilton (Age 55)
Chief Commercial Officer of Rare Diseases

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BHVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings or view top-rated stocks.
What is Biohaven's stock price target for 2024?: 5 analysts have issued 12-month price targets for Biohaven's stock. Their BHVN share price targets range from $24.00 to $36.00. On average, they expect the company's stock price to reach $29.17 in the next twelve months. This suggests that the stock has a possible downside of 12.3%.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.
How have BHVN shares performed in 2023?: Biohaven's stock was trading at $13.88 at the beginning of 2023. Since then, BHVN stock has increased by 139.6% and is now trading at $33.25.
View the best growth stocks for 2023 here.
Are investors shorting Biohaven?: Biohaven saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 6,180,000 shares, a decrease of 8.0% from the October 31st total of 6,720,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 5.3 days. Approximately 10.5% of the company's shares are sold short.
View Biohaven's Short Interest.
When is Biohaven's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our BHVN earnings forecast.
How were Biohaven's earnings last quarter?: Biohaven Ltd. (NYSE:BHVN) announced its earnings results on Tuesday, November, 14th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.33) by $0.17.

What ETFs hold Biohaven's stock?: ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).
What other stocks do shareholders of Biohaven own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).
When did Biohaven IPO?: (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
Who are Biohaven's major shareholders?: Biohaven's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (8.44%), FMR LLC (4.77%), Armistice Capital LLC (2.98%), Avidity Partners Management LP (1.88%), Adage Capital Partners GP L.L.C. (1.82%) and Northern Trust Corp (0.81%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John W Childs, Julia P Gregory, Matthew Buten and Vlad Coric.
View institutional ownership trends.
How do I buy shares of Biohaven?: Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:BHVN) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial